Načítá se...
Losartan and end‐organ protection—lessons from the renaal study
Background: The Reduction in ENdpoints with the Angiotensin Antagonist Losartan (RENAAL) study reported that losartan delayed the progression of renal disease in patients with type 2 diabetes and nephropathy. Diabetic or renally impaired patients are at high cardiovascular risk, a risk potentially i...
Uloženo v:
| Vydáno v: | Clin Cardiol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wiley Periodicals, Inc.
2006
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6654430/ https://ncbi.nlm.nih.gov/pubmed/15813620 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.4960280307 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|